Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

By C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, Bryan T. J. Hennessy, M. Green and 3 more. Journal of Clinical Oncology, 2008

2,849 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a1813d0e60196c1011142d6a3782203db4b3c248

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Pathology and Forensic Medicine

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Deconstructing the molecular portraits of breast cancer (2010, result): “Known as the “triple-negative paradox”, this hypothesis was further tested retrospectively by Liedtke et al. (2008) by comparing response to neoadjuvant chemotherapy and survival using 1118 patients with triplenegative and non-triple-negative breast cancer.”
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “End points in neoadjuvant therapy Failure to achieve pCR among patients with rapidly proliferating tumors identifies a group with a poor prognosis, which may be suitable for early trials of investigational agents [11].”
Triple-negative breast cancer--current status and future directions. (2009, background): “Interestingly, patients experiencing pCR following neoadjuvant chemotherapy had an excellent OS regardless of receptor expression; in contrast, patients who had residual invasive carcinoma after completion of neoadjuvant chemotherapy had a significantly shorter OS associated with TNBC compared with ”
Awareness and current knowledge of breast cancer (2017, background): “Triple-negative breast cancer is described by the deficiency of progesterone receptor, human epidermal growth factor receptor 2 and estrogen receptor expression [56].”
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015, background): “other aggressive cancers, pCR is associated with improved outcomes, whereas patients with residual disease have an increased risk of recurrence.(2,3) Platinum analogs attack cancer cells by inducing doublestranded DNA breaks.”
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012, background): “For example, although patients with luminal A–like breast cancer show a low pCR rate, their overall prognosis is favorable, whereas patients with triple-negative (TN) breast cancer show a high pCR rate but have an unfavorable outcome.(9) Including all intrinsic subtypes might therefore attenuate the”
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies (2010, background): “cancers defined through gene-expression profiling or immunophenotyping are responsive to chemotherapy regimes [31–33].”
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “Despite the aggressive nature of TNBC, 20% of patients present a pathologic complete response (pCR) after neoadjuvant chemotherapy [10].”
PD-L1 Expression in Triple Negative Breast Cancer (2014, neutral): “Cancer Immunol Res; 2(4) April 2014 Cancer Immunology Research 364”
ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “Achievement of a pathological complete response (path CR) in the breast and axillary lymph nodes after neoadjuvant trastuzumab or chemotherapy has been associated with improved long-term outcome (Gianni et al., 2010; Liedtke et al., 2008).”